Idiopathic Pulmonary Fibrosis (IPF) Treatment is Entering its Most Competitive Era Yet - What Thelansis Data Reveals

Executive Summary
Idiopathic Pulmonary Fibrosis remains one of the toughest fights in respiratory medicine. It's a progressive, irreversible scarring of lung tissue with a median survival window that, sobering as it sounds, published clinical literature describes as worse than that of many cancers. For nearly a decade, pirfenidone and nintedanib were the only tools available to slow, never stop, that decline. That finally changed.
• In October 2025, the FDA approved Jascayd (nerandomilast) from Boehringer Ingelheim, marking the first new drug approved for IPF in over a decade
• A wave of late-stage candidates, from oral antifibrotics to inhaled therapies to first-in-class biologics, is now moving through Phase II/III
• The global IPF market is on a clear growth trajectory, with independent estimates placing 2026 values anywhere from roughly USD 3.3-5.4 billion and CAGRs in the 6-9% range through the early 2030s, depending on scope and methodology

For pharma strategy, market access, and business development teams, the real question isn't whether the IPF landscape is shifting; it's where the next commercially defensible position sits once the current wave of launches settles. That's exactly the gap Thelansis's latest report is built to close.

Our new report "Idiopathic Pulmonary Fibrosis (IPF): Emerging Therapy, with Unmet Needs and TPP Insights - 2026" unpacks the competitive landscape, KOL-validated unmet needs, and target product profile (TPP) benchmarking teams need to plan a launch or licensing decision with confidence. Explore the full scope and download a sample: https://thelansis.com/reports/idiopathic-pulmonary-fibrosis-ipf-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/

Key Emerging Players Reshaping the IPF Pipeline
The IPF pipeline has gone from thin to genuinely competitive, and the mechanisms in play are far more diverse than the antifibrotic class that has dominated for years.
• Boehringer Ingelheim - beyond Jascayd's approval, the company has also initiated early-stage work on BI 765423, a first-in-class antibody targeting interleukin-11, a cytokine implicated in fibrotic signaling
• PureTech Health / Celea Therapeutics - deupirfenidone (LYT-100), positioned as a better-tolerated evolution of pirfenidone, showed stabilized lung function in patients transitioning from the randomized phase into its Phase IIb open-label extension and is advancing into the Phase III SURPASS-IPF trial
• Bristol Myers Squibb - admilparant, an LPA1 receptor agonist, is in Phase III with a data readout expected later in 2026
• United Therapeutics - inhaled treprostinil (Tyvaso) is being studied in IPF patients without pulmonary hypertension in the Phase III TETON program, after its positive TETON-2 results • Additional candidates in active development include ENV-101, AZD8965, LTI-03, and PLN-74809, spanning oral, inhaled, and biologic modalities
This diversification matters commercially; it means the next generation of IPF entrants won't just compete on efficacy, but on route of administration, tolerability, and how well they fit into existing treatment algorithms alongside (or after) antifibrotics.
Secure your position in the emerging Idiopathic Pulmonary Fibrosis market by unlocking the critical pipeline benchmarks and TPP data driving the field forward. Request a Sample: https://thelansis.com/reports/idiopathic-pulmonary-fibrosis-ipf-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ipf_tpp

Current Standard of Care: Where It Falls Short
Pirfenidone and nintedanib remain the backbone of IPF management, and for good reason, they're the only therapies with a long track record of slowing functional decline. But neither one is a cure, and both carry real limitations that show up in daily practice:
• Neither drug halts or reverses established fibrosis - they only slow the rate of decline
• Tolerability issues (GI side effects, photosensitivity, liver enzyme changes) drive meaningful rates of dose reduction and discontinuation
• Lung transplantation remains the only potentially life-extending option, but it's available to a small, highly selected patient subset • Generic pirfenidone has since entered the market, applying pricing pressure even as it remains the largest single drug segment by revenue share
The net effect: physicians and patients are still waiting for something that changes the trajectory of the disease, not just the slope of the curve.

Market Drivers and Trends Shaping the Next Decade
A handful of structural forces are converging to expand the IPF opportunity, even as the competitive bar keeps rising:
• Aging populations across the G8 markets are steadily expanding the diagnosed patient pool
• Improved diagnostic capability, better HRCT protocols, biomarker panels, and growing awareness among pulmonologists are pulling more patients into the diagnosed and treated funnel earlier
• Regulatory tailwinds, including orphan drug and breakthrough designations, are shortening pathways for differentiated mechanisms
• Trial activity is increasingly globalizing, with a growing share of studies running across Asia-Pacific sites, improving physician familiarity ahead of launch • Inhaled and next-generation oral formulations are emerging as a differentiation lever against the GI tolerability issues that limit current antifibrotic
Put together, these dynamics mean the market isn't just growing; it's segmenting, with room for therapies that win on mechanism, tolerability, or patient convenience rather than head-to-head efficacy alone.

Get the complete picture on where IPF treatment is headed next. Request a free Sample report: https://thelansis.com/reports/idiopathic-pulmonary-fibrosis-ipf-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ipf_tpp

Unmet Needs and KOL Expectations
Ask any treating pulmonologist what they still need in IPF, and the list hasn't changed much in years, it's just gotten more urgent as more assets enter late-stage trials:
• A therapy that meaningfully halts, not just slows, disease progression
• Better tolerability profiles that support long-term adherence without dose interruptions
• Clearer guidance on combination or sequencing strategy as more mechanisms become available
• Earlier, more reliable diagnostic and prognostic biomarkers to guide treatment initiation
• Realistic expectations on how emerging therapies will actually be used: first-line, add-on, or reserved for antifibrotic-intolerant patients
These aren't abstract wishes, they're the exact criteria KOLs use, often unconsciously, when they decide how quickly to adopt a new therapy once it's approved. Understanding which unmet needs a given TPP genuinely addresses, and which it doesn't, is often the difference between a fast uptake curve and a slow one.

Commercial Opportunity: Where the White Space Sits
With one new approval delivered and several more mechanisms approaching pivotal readouts, IPF is entering a genuinely competitive phase, which is exactly when TPP discipline starts to matter more, not less. The companies that win here won't just be the ones with the best efficacy data; they'll be the ones that design a profile around the specific gaps current and emerging competitors leave open.
For business development, portfolio strategy, and market access leads, the practical questions are:
• Which unmet needs remain unaddressed even after the current pipeline reads out?
• How should a candidate be positioned: first-line replacement, combination partner, or niche/refractory-segment therapy?
• What target attributes (efficacy threshold, safety margin, dosing convenience, price point) actually move physician prescribing intent?
• Where does licensing or in-market partnership make more sense than in-house development?
Thelansis's "Idiopathic Pulmonary Fibrosis (IPF) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" was built to answer exactly this set of questions combining competitive landscape mapping, primary KOL research, and target product profile modeling across the U.S., EU5, Japan, and China.

Ready to see how your program, or a target asset, stacks up against the Idiopathic Pulmonary Fibrosis (IPF) TPP landscape? Explore the full table of contents: https://thelansis.com/reports/idiopathic-pulmonary-fibrosis-ipf-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ipf_tpp

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.